Evidence Level for Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists Respectively Sodium Glucose Co-Transporter-2 Inhibitors for Mitochondrial Diabetes Is Low. ijmhs 2020, 10 (06), 959-960.